In recent months as vaccines against the SARS-CoV-2 virus continue to rollout across the globe, there has been a renewed interest in ways to activate or ignite the immune system. For a vaccine to be effective, it must be immunogenic and specific to provoke the body's defenses to mount an effective response that protects the host from disease. However, there are other situations wherein the immune system mounts an unwanted immune response that can be detrimental to health, either directly, by causing an autoimmune disease, or indirectly, by compromising the safety and/or efficacy of biologic drugs. In these scenarios, it would be desirable to have a ‘tolerogenic vaccine’ that could selectively and effectively mitigate these unwanted immune responses. ImmTORTM, a nanoparticle technology, is being developed to address the issue of immunogenicity for gene therapy vectors and other biologic drugs. By targeting antigen-presenting cells, ImmTORTM has the potential to amplify the efficacy of biologic therapies and unlock the full potential of such treatments to improve the lives of those who suffer from serious and debilitating diseases.
Skip Nav Destination
Article navigation
November 2021
-
Cover Image
Cover Image
This special issue of Emerging Topics in Life Sciences (volume 5, issue 5) brings together a collection of perspectives about innovative techniques and ideas from scientists working in the life sciences industry. The cover image is an illustration featured in the piece discussing by ImmTOR™ by Brunn and Kishimoto.
Perspective|
August 13 2021
ImmTORTM to amplify the efficacy and reduce immunogenicity of biologics Available to Purchase
Carsten Brunn
;
Selecta Biosciences, Inc., Watertown, MA, U.S.A.
Correspondence: Carsten Brunn ([email protected])
Search for other works by this author on:
Takashi Kei Kishimoto
Takashi Kei Kishimoto
Selecta Biosciences, Inc., Watertown, MA, U.S.A.
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
May 19 2021
Revision Received:
July 26 2021
Accepted:
July 29 2021
Online ISSN: 2397-8562
Print ISSN: 2397-8554
© 2021 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society and the Royal Society of Biology
2021
Emerg Top Life Sci (2021) 5 (5): 597–600.
Article history
Received:
May 19 2021
Revision Received:
July 26 2021
Accepted:
July 29 2021
Citation
Carsten Brunn, Takashi Kei Kishimoto; ImmTORTM to amplify the efficacy and reduce immunogenicity of biologics. Emerg Top Life Sci 12 November 2021; 5 (5): 597–600. doi: https://doi.org/10.1042/ETLS20210127
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.